Glutamic acid decarboxylase autoantibody syndrome presenting as schizophrenia

Neurologist

Volumn 18, Issue 2, 2012, Pages 88-91

  Najjar, Souhel ^a,b   Pearlman, Daniel ^b   Zagzag, David ^b   Golfinos, John ^b   Devinsky, Orrin ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

antibodies; autoimmune; brain biopsy; glutamic acid decarboxylase; schizophrenia

Indexed keywords

GLUTAMATE DECARBOXYLASE ANTIBODY; IMMUNOGLOBULIN; PREDNISONE;

ADULT; ANTIBODY TITER; ARTICLE; ASTROCYTOSIS; AUTOIMMUNE DISEASE; BRAIN BIOPSY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EXECUTIVE FUNCTION; FEMALE; GLIOSIS; GLUTAMIC ACID DECARBOXYLASE AUTOANTIBODY SYNDROME; HUMAN; IMMUNOTHERAPY; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; STEROID THERAPY; WECHSLER INTELLIGENCE SCALE;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84858136715     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e318247b87d     Document Type: Article

References (13)

1. Thompson M, Weickert CS, Wyatt E, et al. Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J Psychiatr Res. 2009;43:970-977.
2. Bird ED, Spokes EG, Barnes J, et al. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet. 1977;2:1157-1158.
3. Guidotti A, Auta J, Davis JM, et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl). 2005;180:191-205. (Pubitemid 40909664)
4. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131: 2553-2563.
5. Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005;128:1764-1777. (Pubitemid 41373648)
6. Matà S, Muscas GC, Naldi I, et al. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol. 2008;199:155-159.
7. Blanc F, Ruppert E, Kleitz C, et al. Acute limbic encephalitis and glutamic acid decarboxylase: a reality? J Neurol Sci. 2009; 287:69-71.
8. Saiz A, Arpa J, Sagasta A, et al. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology. 1997;49:1026-1030.
9. Marchiori GC, Vaglia A, Vianello M, et al. Encephalitis associated with glutamic acid decarboxylase autoantibodies. Neurology. 2001;56:814. (Pubitemid 32240113)
10. Kobyakawa Y, Tateishi T, Kawamura N, et al. A case of immune-mediated encephalopathy showing refractory epilepsy and extensive brain MRI lesions associated with anti-glutamic acid decarboxylase antibody. Rinsho Shinkeigaku. 2010;50:92-97.
11. + T cells. J Immunol. 2010;184:4863-4870.
12. Bernstein HG, Steiner J, Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother. 2009;9:1059-1071.
13. Liimatainen S, Peltola M, Sabater L, et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia. 2010;51:760-767.